X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Fabagal (agalsidase-beta) is a recombinant analogue of human alpha-galactosidase A and is produced by recombinant DNA technology. It is approved for the treatment of fabry disease in adults and children from 8 years old.
Lead Product(s): Agalsidase Beta
Therapeutic Area: Genetic Disease Product Name: Fabagal
Highest Development Status: ApprovedProduct Type: Large molecule
Recipient: Petrovax
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 02, 2023
Details:
YH003 is a humanized IgG2 agonistic CD40 antibody. Whether used as a single agent or in combination with anti-PD-1 monoclonal antibody drugs, YH003 demonstrated strong anti-tumor effects against multiple tumor.
Lead Product(s): Tri-specific Antibody
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Recipient: Eucure Biopharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership November 01, 2022
Details:
Under the terms of the agreement, ISU ABXIS will utilize the sequence of YH003, Biocytogen’s humanized agonistic anti-CD40 antibody currently in phase II clinical trials, to construct a few groups of tri-specific antibodies and develop cancer drugs for multiple indications.
Lead Product(s): YH003,Toripalimab
Therapeutic Area: Oncology Product Name: YH003
Highest Development Status: Phase IIProduct Type: Large molecule
Recipient: Eucure Biopharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 31, 2022
Details:
Abcertin (Imiglucerase) is an orphan drug independently developed by Isu Abxis, is an Enzyme Replacement Therapy (ERT) treatment for Gaucher disease with the same ingredient name as Cerezyme.
Lead Product(s): Imiglucerase
Therapeutic Area: Genetic Disease Product Name: Abcertin
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 22, 2022
Details:
Abcertin (Imiglucerase) is an orphan drug independently developed by Isu Abxis, is an Enzyme Replacement Therapy (ERT) treatment for Gaucher disease with the same ingredient name as Cerezyme.
Lead Product(s): Imiglucerase
Therapeutic Area: Genetic Disease Product Name: Abcertin
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 12, 2022
Details:
Under the agreement, Petrovax gains access to Fabagal (agalsidase beta), indicated for long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease (α-galactosidase A deficiency).
Lead Product(s): Agalsidase Beta
Therapeutic Area: Genetic Disease Product Name: Fabagal
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Petrovax
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 26, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
